All News

Pandemic-related growing pains were common within health care, bringing unique challenges for health systems.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses the role of the pharmacist in relation to bispecific care team readiness and patient readiness.

Treatment with LYT-200 is currently being assessed in a phase 1/2 adaptive design trial in advanced/metastatic solid tumors and in a phase 1b clinical trial.

In this NCCN session, James M. Foran, MD, described the different FLT3 inhibitors that are available for FLT3-mutated AML, as well as considerations for the future.

In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma.

The designation was granted based on overall survival data from an ongoing randomized phase 2 clinical trial.

In addition to oral administration, patients with partial-onset seizures can now take the antiseizure medication via a nasogastric tube if the tablet is crushed and mixed with water.

Both dual primary endpoints—progression-free survival and overall survival—were met with durvalumab.

The pharmacist integration model filled in gaps in care that appeared to positively affect MIPS and PCMH quality measures.

Jonathan Levitt, Esq, discusses legislation and legal action taken to rein in pharmacy benefit managers’ DIR fees.

The antibody drug conjugate was used in combination with the anti-cancer drug SG3249, and demonstrated efficacy in mouse models after 1 week.

Scott Soefje, PharmD, BCOP, FCCP, FHOPA, MBA, addresses some of the key steps pharmacists should take when conducting a financial analysis for cancer drugs.

Whitney Lewis, PharmD, BCOP, discusses how the treatment armamentarium for NSCLC has expanded in recent years and the associated cause for this acceleration.

Benralizumab was previously approved by the FDA in 2017 as an add-on maintenance therapy for patients 12 years and older.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some of the considerations for bispecifics in relation to facility readiness at different sites and among different stakeholders.

James Shehan shares insights on the promising trends shaping the weight loss medication and how changing views of obesity could pave the way for uptake GLP-1s.

Tune into this episode of “Public Health Matters” to learn about Dr. Pauline K. Long and her entrepreneurship journey, as well as how she creates meaningful impacts on patients in marginalized communities and within public health.

Danielle Roman, PharmD, BCOP, discusses how the role of the oncology pharmacist has changed in recent years in optimizing early-stage breast cancer treatment with targeted therapies.

Karen Fancher, PharmD, BCOP, discusses some guiding principles for oncology pharmacists when facing ethical dilemmas and provides some recommendations for navigating those challenges.

The results demonstrated similar overall survival between patients with chronic lymphocytic leukemia who discontinued specialized follow-ups versus those who continued.

Pharmacists can help to interpret HbA1c and glucose results when patients come to pick up medications and contact prescribers and/or make recommendations based off patient results.

However, psychedelic medicine has a variety of barriers, including historical perception, access challenges, legal obstacles, and ethical questions.

The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.

Venetoclax, which is approved for leukemia, blocks a function of the BCL-2 protein and has previously shown efficacy in a small proportion of patients with multiple myeloma.

In a review, investigators focused on ranibizumab (Lucentis; Genentech), aflibercept (Eylea; Regeneron), and bevacizumab (Avastin; Genentech) as growth opportunities in the biosimilar space.

Investigators found that older adults, adults with dementia, and adults with altered mental status were more likely to be inappropriately diagnosed with CAP when hospitalized.

Pharmacists should be well educated on prescription digital therapeutics to better educate patients on software in comparison to traditional pharmacological products.

Pharmacists can address social determinants to improve patient well-being and treatment.

Challenges in treating insomnia in special groups and resistant cases, and ways for pharmacists to improve outcomes.

Linking strong anticholinergic medications to increased risk of dementia in older adults